AU2020353055A8 - Antiviral pyrazolopyridinone compounds - Google Patents

Antiviral pyrazolopyridinone compounds Download PDF

Info

Publication number
AU2020353055A8
AU2020353055A8 AU2020353055A AU2020353055A AU2020353055A8 AU 2020353055 A8 AU2020353055 A8 AU 2020353055A8 AU 2020353055 A AU2020353055 A AU 2020353055A AU 2020353055 A AU2020353055 A AU 2020353055A AU 2020353055 A8 AU2020353055 A8 AU 2020353055A8
Authority
AU
Australia
Prior art keywords
compounds
antiviral
pyrazolopyridinone
pyrazolopyridinone compounds
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2020353055A
Other versions
AU2020353055A1 (en
AU2020353055B2 (en
Inventor
Britton K. Corkey
Zef KONST
Yipin Lu
Samuel E. Metobo
Robert Joseph MOREAU
Naomi Samadara Rajapaksa
Galen SHEARN-NANCE
David Charles TULLY
Michael Robert Turner
Joseph Michael YOUNG
Qian Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Gilead Sciences Inc
Original Assignee
Novartis AG
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Gilead Sciences Inc filed Critical Novartis AG
Publication of AU2020353055A1 publication Critical patent/AU2020353055A1/en
Publication of AU2020353055A8 publication Critical patent/AU2020353055A8/en
Application granted granted Critical
Publication of AU2020353055B2 publication Critical patent/AU2020353055B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.
AU2020353055A 2019-09-26 2020-09-24 Antiviral pyrazolopyridinone compounds Active AU2020353055B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962906664P 2019-09-26 2019-09-26
US62/906,664 2019-09-26
PCT/US2020/052375 WO2021061898A1 (en) 2019-09-26 2020-09-24 Antiviral pyrazolopyridinone compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024203782A Division AU2024203782A1 (en) 2019-09-26 2024-06-05 Antiviral pyrazolopyridinone compounds

Publications (3)

Publication Number Publication Date
AU2020353055A1 AU2020353055A1 (en) 2022-05-19
AU2020353055A8 true AU2020353055A8 (en) 2022-09-29
AU2020353055B2 AU2020353055B2 (en) 2024-03-07

Family

ID=72944229

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020353055A Active AU2020353055B2 (en) 2019-09-26 2020-09-24 Antiviral pyrazolopyridinone compounds

Country Status (10)

Country Link
US (2) US11667613B2 (en)
EP (1) EP4034537A1 (en)
JP (2) JP7417715B2 (en)
KR (1) KR20220070005A (en)
CN (1) CN114667285A (en)
AR (1) AR120045A1 (en)
AU (1) AU2020353055B2 (en)
CA (1) CA3155287A1 (en)
TW (1) TW202126649A (en)
WO (1) WO2021061898A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024049803A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Bicyclic heterocycle compounds for treatment of herpes viruses

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0090505B1 (en) 1982-03-03 1990-08-08 Genentech, Inc. Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it
US4661493A (en) 1985-03-29 1987-04-28 Pfizer Inc. Tioconazole and related compounds for control of Herpes simplex virus
CA1340683C (en) 1989-07-07 1999-07-27 Pierre Louis Beaulieu Antiherpes pentapeptides having a substituted aspartic acid side chain
CA1340911C (en) 1989-07-07 2000-02-22 Julian Adams Antiherpes cyclic peptides
CA1340684C (en) 1989-07-07 1999-07-27 Pierre Louis Beaulieu Antiherpes pentapeptides
CA2018801C (en) 1990-06-12 2000-08-22 Pierre Louis Beaulieu Antiherpes peptide derivatives having a 1,4-dioxo c n-terminus
CA2033448C (en) 1990-12-31 1996-11-26 Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee Antiherpes compositions and method of use
ATE169931T1 (en) 1992-03-12 1998-09-15 Boehringer Ingelheim Ca Ltd ISOSTERIC PEPTIDE DERIVATIVES AGAINST HERPES
US5830864A (en) 1992-03-12 1998-11-03 Boehringer Ingelheim (Canada), Ltd. Antiherpes peptide derivatives having a ureido n-terminus
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
JP4327249B2 (en) 1995-12-29 2009-09-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Phenylthiazole derivatives with anti-herpesvirus properties
DE19621038A1 (en) 1996-05-24 1997-11-27 Boehringer Ingelheim Kg Aminoguanidines, processes for their preparation and medicaments containing these compounds
DE69738749D1 (en) 1996-08-16 2008-07-17 Schering Corp CELL SURFACE ANTIGEN FROM MAMMALS AND RELATED REAGENTS
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
JP2002505660A (en) 1996-09-10 2002-02-19 ファルマシア・アンド・アップジョン・カンパニー 8-Hydroxy-7-substituted quinolines as antiviral agents
ES2244048T3 (en) 1997-02-14 2005-12-01 G.D. Searle Llc. USE OF COMPOUNDS (N) -Substituted-1,5-DIDESOXI-1,5-IMINO-D-GLUCITOL IN COMBINATION THERAPY FOR THE TREATMENT OF INFECTIONS WITH HEPATITIS VIRUSES.
DE69811062T2 (en) 1997-04-10 2003-07-17 Upjohn Co POLYAROMATIC ANTIVIRAL COMPOSITIONS
PT1021404E (en) 1997-10-07 2003-04-30 Boehringer Ingelheim Ca Ltd AZETIDINONE DERIVATIVES FOR THE TREATMENT OF INFECTIONS BY HCMV
DK1023265T3 (en) 1997-10-07 2003-02-24 Boehringer Ingelheim Ca Ltd Azetidinone derivatives for the treatment of HCMV infections
DE69808326T2 (en) 1997-10-07 2003-05-22 Boehringer Ingelheim Ca Ltd AZETIDINE DERIVATIVES FOR TREATING HCMV INFLAMMATION
EP1025228A4 (en) 1997-10-21 2002-09-18 Human Genome Sciences Inc Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
NZ503809A (en) 1997-12-19 2002-04-26 Schering Ag Ortho-anthranilamide derivatives as anti-coagulants
ES2248923T3 (en) 1997-12-22 2006-03-16 PHARMACIA & UPJOHN COMPANY LLC 4-HYDROXIQUINOLIN-3-CARBOXAMIDS AND HYDRAZIDS AS ANTIVIRAL AGENTS.
AU2591599A (en) 1998-02-09 1999-08-23 Genentech Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
AU743489B2 (en) 1998-03-19 2002-01-24 Pharmacia & Upjohn Company 1,3,4-thiadiazoles useful for the treatment of CMV infections
AU759711B2 (en) 1998-12-23 2003-04-17 Bristol-Myers Squibb Holdings Ireland Unlimited Company Nitrogen containing heterobicycles as factor XA inhibitors
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
ES2184705T3 (en) 1999-03-09 2003-04-16 Upjohn Co 4-OXO-4,7-DIHIDRO-TIENO (2,3-B) PIRIDINA-5-CARBOXAMIDS AS ANTIVIRAL AGENTS.
JP3762868B2 (en) 1999-03-25 2006-04-05 ベーリンガー インゲルハイム （カナダ） リミテッド HSV primase inhibitor
PT1196186E (en) 1999-07-12 2008-02-14 Genentech Inc Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
TW500724B (en) 1999-10-05 2002-09-01 Pharmacia & Amp Upjohn Company Oxazinoquinolones useful for the treatment of viral infections
WO2001081318A1 (en) 2000-03-21 2001-11-01 Pharmacia & Upjohn Company 4-hydroxycinnoline-3-carboxyamides as antiviral agents
JP2003528087A (en) 2000-03-21 2003-09-24 ファルマシア・アンド・アップジョン・カンパニー 4-oxo-1,4-dihydro-3-cinnolinecarboxamide as antiviral agent
NZ521523A (en) 2000-03-21 2004-05-28 Upjohn Co 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents
MXPA02009249A (en) 2000-03-21 2003-03-12 Upjohn Co 4 oxo 1,4 dihydro[1,8]naphthyridine 3 carboxamides as antiviral agents.
EE200200567A (en) 2000-03-31 2004-06-15 Pfizer Products Inc. New piperazine derivatives
PE20011349A1 (en) 2000-06-16 2002-01-19 Upjohn Co 1-ARIL-4-OXO-1,4-DIHYDRO-3-QUINOLINE CARBOXAMIDES AS ANTIVIRAL AGENTS
US6525049B2 (en) 2000-07-05 2003-02-25 Pharmacia & Upjohn Company Pyrroloquinolones as antiviral agents
US6559145B2 (en) * 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
EP1299395B1 (en) 2000-07-12 2004-09-15 PHARMACIA & UPJOHN COMPANY Oxazinoquinolones useful for the treatment of viral infections
US6624159B2 (en) 2000-07-12 2003-09-23 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6682892B2 (en) 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
TWI287004B (en) 2000-12-28 2007-09-21 Shionogi & Co A pyridone derivative having an affinity effect for cannabinoid 2 type receptor
US6821969B2 (en) 2001-02-13 2004-11-23 Pharmacia & Upjohn Company Thioxazinoquinolones as antiviral agents
CA2433467A1 (en) 2001-03-01 2002-09-12 Joseph W. Strohbach Substituted quinolinecarboxamides as antiviral agents
MXPA04001797A (en) 2001-08-30 2004-07-08 Pharmacia & Upjhon Company 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANT IVIRAL AGENTS.
WO2003020728A1 (en) 2001-08-30 2003-03-13 Pharmacia & Upjohn Company 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
RU2345993C2 (en) 2001-09-21 2009-02-10 Бристол-Маерс Сквибб Компани LACTAM-CONTAINING COMPOUND AND ITS DERIVATIVES AS Xa FACTOR INHIBITORS
CA2471089A1 (en) 2001-12-20 2003-07-03 Pharmacia & Upjohn Company Pyridoquinoxaline antivirals
EP1456208A1 (en) 2001-12-20 2004-09-15 PHARMACIA & UPJOHN COMPANY Pyridoquinoxaline antivirals
AR038294A1 (en) 2002-01-14 2005-01-12 Upjohn Co OXOTIENE (3,2-B) PYRIDINCARBOXAMIDS AS ANTIVIRAL AGENTS
AR038118A1 (en) 2002-01-14 2004-12-29 Upjohn Co COMPOUNDS DERIVED FROM ACID BENCINAMIDE 7-OXO-4,7-DIHIDROTIEN [2,3-B [PIRIDIN-6-CARBOXYLIC 3-REPLACED WHICH ARE USEFUL AS ANTIVIRAL
AR038117A1 (en) 2002-01-14 2004-12-29 Upjohn Co ANTIVIRAL AGENTS DERIVED FROM 4- OXO-4,7 -DIHYDROFIDE [2,3-B] PIRIDIN-5-CARBOXAMIDA
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2003099276A1 (en) 2002-05-10 2003-12-04 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
WO2004022567A1 (en) 2002-09-04 2004-03-18 Pharmacia & Upjohn Company Llc Heteroaryl-ethanolamine derivatives as antiviral agents
US6831081B2 (en) 2002-09-04 2004-12-14 Pharmacia & Upjohn 4-Oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents
US20050049245A1 (en) 2002-09-04 2005-03-03 Schnute Mark E. Heteroaryl-ethanolamine derivatives as antiviral agents
WO2004106345A2 (en) 2002-09-04 2004-12-09 Pharmacia & Upjohn Company Heteroaryl-ethanolamine derivatives as antiviral agents
ES2367430T3 (en) 2002-12-23 2011-11-03 Wyeth Llc ANTIBODIES AGAINST PD-1 AND ITS USES.
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
DE10319612A1 (en) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituted dihydroquinazolines
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
EP1460075A1 (en) 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives
EP1610782A1 (en) 2003-03-27 2006-01-04 Boehringer Ingelheim International GmbH Antiviral combination of a dipyridodiazepinone and a further antiretroviral compound
EP1610797A1 (en) 2003-03-27 2006-01-04 Boehringer Ingelheim International GmbH Antiviral combination of nevirapine and a further antiretroviral compound
AU2004244626A1 (en) 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
CN1863793A (en) 2003-06-11 2006-11-15 三共株式会社 Cyclic tertiary amine compound
WO2005007190A1 (en) 2003-07-11 2005-01-27 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
WO2005012545A2 (en) 2003-07-25 2005-02-10 The Regents Of The University Of California Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors
CL2004002050A1 (en) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B COMPOUNDS DERIVED FROM REPLACED PIRIDINONES; ITS USE IN THE TREATMENT OF AFFECTIONS CAUSED OR EXACTED BY ACTIVITY P38 MAP KINASA AND / OR NON-REGULATED TNF, SUCH AS INFLAMMATIONS, TUMORS, AIDS AND OTHERS.
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
WO2005055808A2 (en) 2003-12-02 2005-06-23 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer
EP1718152A4 (en) 2004-01-28 2009-09-16 Merck & Co Inc Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
US20060002932A1 (en) 2004-06-04 2006-01-05 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
EP2343320B1 (en) 2005-03-25 2017-10-25 GITR, Inc. Anti-gitr antibodies and uses thereof
ES2427646T5 (en) 2005-05-09 2017-08-22 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies against programmed death 1 (PD1) and methods for the treatment of cancer through the use of anti-PD-1 antibodies alone or in combination with other immunotherapeutic agents
MX2007015942A (en) 2005-07-01 2008-03-07 Medarex Inc Human monoclonal antibodies to programmed death ligand 1 (pd-l1).
BRPI0615133A2 (en) 2005-08-23 2011-05-03 Irm Llc immunosuppressive compounds, pharmaceutical compositions containing them as well as said use
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
RU2008132333A (en) 2006-02-07 2010-03-20 Вайет (Us) 11-BETA HSD1 INHIBITORS
CA2686138A1 (en) 2007-05-03 2008-11-13 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
RS53072B (en) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
JP5932217B2 (en) 2007-07-12 2016-06-08 ジーアイティーアール， インコーポレイテッド Combination therapy using GITR binding molecules
CA2707030A1 (en) 2007-08-03 2009-02-12 Pfizer Limited Imidazopyridinones
PT2242773T (en) 2008-02-11 2017-09-15 Cure Tech Ltd Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2010003118A1 (en) 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Tgf-b antagonist multi-target binding proteins
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
JP2012501991A (en) 2008-09-03 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of quinazoline derivatives for the treatment of viral diseases
US8586023B2 (en) 2008-09-12 2013-11-19 Mie University Cell capable of expressing exogenous GITR ligand
HUE034832T2 (en) 2008-12-09 2021-12-28 Hoffmann La Roche Anti-pd-l1 antibodies and their use to enhance t-cell function
US8741295B2 (en) 2009-02-09 2014-06-03 Universite De La Mediterranee PD-1 antibodies and PD-L1 antibodies and uses thereof
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
AU2010343057B2 (en) 2009-12-29 2017-02-23 Aptevo Research And Development Llc Heterodimer binding proteins and uses thereof
AR085286A1 (en) 2011-02-21 2013-09-18 Taisho Pharmaceutical Co Ltd MACROLIDO DERIVATIVE REPLACED IN POSITION C-4
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
JP6138813B2 (en) 2011-11-28 2017-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Anti-PD-L1 antibody and use thereof
WO2013085890A1 (en) 2011-12-06 2013-06-13 Glaxo Group Limited Therapeutic methods
US9315499B2 (en) 2012-04-05 2016-04-19 Boehringer Ingelheim International Gmbh Cytomegalovirus inhibitor compounds
CA2873882C (en) 2012-04-05 2020-12-15 Boehringer Ingelheim International Gmbh 1,8-naphthyridin-2(1h)-one derivatives as cytomegalovirus inhibitors
AU2013261023B2 (en) 2012-05-16 2016-11-24 Cellzome Limited Substituted 3, 4 - dihydro - 2H - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) Alzheimer's disease
UY34887A (en) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
EP2914591B1 (en) 2012-11-03 2017-10-11 Boehringer Ingelheim International GmbH Inhibitors of cytomegalovirus
WO2014070979A1 (en) 2012-11-03 2014-05-08 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
JP6237779B2 (en) 2012-11-03 2017-11-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cytomegalovirus inhibitor
US9999690B2 (en) 2013-11-08 2018-06-19 Perosphere Pharmaceuticals Inc. Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds
EP3126361B1 (en) 2014-04-01 2019-11-06 Pfizer Inc Chromene and 1,1a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
EP3126362B1 (en) 2014-04-02 2022-01-12 Intermune, Inc. Anti-fibrotic pyridinones
JP6271806B2 (en) 2014-04-11 2018-01-31 パノプテス・ファーマ・ゲーエムベーハー Anti-inflammatory agents as virus quiescent compounds
TW201808914A (en) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 Modulators of the integrated stress pathway
CN107936016A (en) 2018-01-17 2018-04-20 董丹丹 The preparation method of the medicine Eliquis intermediate of venous thronbosis after prevention buttocks and knee replacement operation
CN108178757A (en) 2018-01-17 2018-06-19 董丹丹 A kind of preparation method for the Eliquis for treating deep vein thrombosis and pulmonary embolism disease
WO2020053654A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds

Also Published As

Publication number Publication date
AR120045A1 (en) 2022-01-26
KR20220070005A (en) 2022-05-27
AU2020353055A1 (en) 2022-05-19
JP2022549650A (en) 2022-11-28
CN114667285A (en) 2022-06-24
US20230365511A1 (en) 2023-11-16
JP7417715B2 (en) 2024-01-18
US20210130302A1 (en) 2021-05-06
JP2024041852A (en) 2024-03-27
US11667613B2 (en) 2023-06-06
TW202126649A (en) 2021-07-16
EP4034537A1 (en) 2022-08-03
CA3155287A1 (en) 2021-04-01
AU2020353055B2 (en) 2024-03-07
WO2021061898A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12018501736A1 (en) Tetracyclic pyridone compounds as antivirals
MX2022010520A (en) Peptide macrocycles against acinetobacter baumannii.
MX2023009185A (en) Benzamide compounds.
MX2021013075A (en) Oxysterols and methods of use thereof.
MX2021006902A (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection.
MX2018000916A (en) Benzodiazepine derivatives as rsv inhibitors.
MX2018005890A (en) Compositions for treating spinal muscular atrophy.
EP4316591A3 (en) Oxysterols and methods of use thereof
SG10201811384TA (en) Mnk inhibitors and methods related thereto
EA202090530A1 (en) 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
MX2020011449A (en) Oxysterols and methods of use thereof.
EA201891063A1 (en) DERIVATIVES OF DIHYDROIMIDAZOPIRAZINONE APPLICABLE IN THE TREATMENT OF CANCER
TN2019000170A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
AU2016229966A8 (en) Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
AU2020231934A8 (en) Compounds useful in HIV therapy
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
BR112017000246A2 (en) compound, pharmaceutically acceptable salt of a compound, pharmaceutical composition, and use of a compound or salt
MX2021004182A (en) Macrocyclic flu endonuclease inhibitors.
EP4342473A3 (en) Compounds useful in hiv therapy
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
AU2020353055A8 (en) Antiviral pyrazolopyridinone compounds
WO2022104153A3 (en) Compounds and methods for treating viral infections

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 36 , NO 20 , PAGE(S) 2767 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME NOVARTIS AG, APPLICATION NO. 2020353055, UNDER INID (71) ADD CO-APPLICANT GILEAD SCIENCES, INC.